MedPath

A Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures

Not Applicable
Completed
Conditions
Type II and IIa Open Tibia Fractures
Registration Number
NCT01315392
Lead Sponsor
Wake Forest University Health Sciences
Brief Summary

Delayed wound closure is considered by many to be the standard of care for the treatment of an open fracture. This study was conducted to determine the feasibility of a large multi-center prospective randomized clinical trial and collect the pilot data needed to compete for the funding for such a trial. The study was designed to compare immediate and delayed closure of Gustilo type II and IIIa tibia diaphyseal fractures. The primary outcomes were the infection rates and fracture related complications in patients treated with immediate or delayed wound closure strategies.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
451
Inclusion Criteria
  • Gustilo type II-IIIa tibia fracture
  • age greater than 15 years
  • fractures amenable to intramedullary nailing
Exclusion Criteria
  • excessive wound contamination
  • patient cardio-pulmonary or hemodynamic instability preventing prompt surgical intervention
  • impaired or absent consciousness
  • refusal of consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
infection rate

defined as cases determined definitively by a positive culture or treated empirically based on tenderness, erythema, and heat at the wound site.

hospital readmissions

need for additional procedures and hospital readmissions related to the index injury will be documented

tibial fracture healing

evidence of bridging callus on three of four cortices assessed by biplanar radiograph

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Carolinas Medical Center

🇺🇸

Charlotte, North Carolina, United States

Carolinas Medical Center
🇺🇸Charlotte, North Carolina, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.